Biotech firm stocks rise on FDA vaccine head's exit
Source: SeekingAlpha
2026-03-09 09:40:31 ET
More on uniQure, Regenxbio, etc.
- Assessing Where Regenxbio Stands After FY25 Results
- REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript
- uniQure: Worst Case Scenario Becomes Reality
- uniQure surges following departure of key FDA official
- Solid Biosciences announces $240 million private placement
Read the full article on Seeking Alpha
For further details see:
Biotech firm stocks rise on FDA vaccine head’s exit
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
17.33% G/L:
$8.60 Last:
1,840,591 Volume:
$8.30 Open:
REPL Latest News
February 03, 2026 08:00:00 am
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
December 18, 2025 08:00:00 am
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
